Jussi Holopainen, MSc (Econ.), BSc (Pharm.)
Jussi Holopainen is the Chairman of the Board of Aranda Pharma Ltd. Jussi has more than 25 years of experience in various managerial positions in Pharmaceutical industry in Finland, Denmark, UK and Mexico. His previous positions have included e.g. Business Development Executive at ICI Pharmaceuticals, Managing Director at ICI Chemicals, Commercial Director at Zeneca Pharma Mexicana, Managing Director at GlaxoWellcome Finland, Managing Director at Tamro Finland and CEO of Pharmatory Finland. Jussi has a strong background in pharmaceutical industry especially in marketing, sales, R&D, production, finance and international operations. Jussi received his MSc in Economy from Vaasa School of Business and BSc in Pharmacy from Kuopio University. He is currently a Board Professional and serves at the Boards of several Life Science companies.
Aki Prihti, MSc (Econ, BA)
Aki Prihti is a Non-Executive Director of Aranda Pharma Ltd. Aki has over 15 years of experience with life science growth companies, both in operational and board roles and as an investor. Aki is one of the founders of Inveni Capital, a life sciences focused venture capital fund. Aki has been involved in setting up, developing, as well as fundraising for, several life science companies and serves currently as a board member in Aranda Pharma Oy, Herantis Pharma Oyj and Priaxon AG. Previously Aki has served in the boards of among others Medeia Therapeutics Oy, Medtentia International Oy and Onbone Oy and has worked for an international investment bank in London. Aki received his MSc in Economy and Business Administration from Helsinki School of Economics and Business Administration, Finland. Currently Aki serves as CEO of Aplagon Oy, a Finnish drug development company focused on vascular intervention related thrombosis.
Kanyin E. Zhang, PhD
Kanyin E. Zhang is a Non-Executive Director of Aranda Pharma Ltd. Kanyin has more than 20 years of experience in drug discovery and development from both US and China. Kanyin began his pharmaceutical research career in the US and held various positions from Research Scientist to Director of DMPK/Pharmacology at Merck, Agouron/Pfizer and GNF (Genomics Institute of the Novartis Research Foundation), and he has been involved in the development of two marketed products and a dozen clinical candidates. After returning to China, he joined Argusina Biosciences, a drug discovery startup founded by Morningside, as a founding member, vice president and general manager at its Shanghai R&D center. Kanyin received his Ph.D. degree from the School of Pharmacy at the University of Washington, Seattle. Currently Kanyin serves as founding CEO of Tarrex Biopharma Ltd, a Chinese drug discovery company developing anti-cancer therapeutics.